13810
post-template-default,single,single-post,postid-13810,single-format-standard,strata-core-1.0.1,strata-child-theme-ver-1.0.0,strata-theme-ver-3.0.3,ajax_fade,page_not_loaded,wpb-js-composer js-comp-ver-6.0.3,vc_responsive

COVID-19: Screening for healthy volunteers has begun to take place at University of Oxford

10:40 31 March in Life Sciences & Healthcare, News, Oxfordshire, Talent and Innovation

A collaboration between the University of Oxford’s Jenner Institute and Oxford Vaccine Group clinical teams will enrol heath volunteers between the ages of 18 and 55, who pass screening, to be the first people to test the new vaccine.

Researchers are working as quickly as possible to get the new vaccine, called ChAdOx1 nCoV-19, ready to be used in the trail, which includes further preclinical investigation and production of a larger number of doses of the vaccine.

Whilst the team will start screening people now to see if they are eligible to take part in the study, participants will not receive the vaccine for some weeks due to necessary detailed preclinical work and the need for the vaccine to be manufactured to clinical grade standard.

“The Oxford team had exceptional experience of a rapid vaccine response, such as to the Ebola outbreak in West Africa in 2014. This is an even greater challenge. Vaccines are being designed from scratch and progressed at an unprecedented rate. The upcoming trial will be critical for assessing the feasibility of vaccination against COVID-19 and could lead to early deployment.”

Professor Adrian Hill, Director of the Jenner Institute at the University of Oxford

 

At the same time as conducting the first clinical trial, production of the vaccine is being scaled up ready for larger trials, and potentially, future deployment. By starting vaccine manufacturing scale-up immediately, the team can ensure that enough vaccine doses are available as soon as possible – especially for NHS workers, the elderly and those with underlying health conditions – if the trials prove that the vaccine is safe and effective.

“The scale of this epidemic poses a huge challenge for vaccine manufacturing. We need to follow rigorous safety standards and that takes time. By starting work on large-scale manufacturing immediately, we hope to accelerate the availability of high quality, safe vaccine.”

Dr Sandy Douglas, who is leading a collaboration working on the vaccine manufacturing scale-up project

 

Read more, HERE.